Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer
Tumor development is angiogenesis dependent, and vascular endothelial growth factor (VEGF) is a key growth factor in this process. We demonstrate that high expression of VEGF mRNA in 55 superficial bladder cancers was associated with earlier recurrence (P = 0.001; hazard ratio, 3.09) and progression...
Gespeichert in:
| Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 1997-12, Vol.57 (23), p.5281-5285 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5285 |
|---|---|
| container_issue | 23 |
| container_start_page | 5281 |
| container_title | Cancer research (Chicago, Ill.) |
| container_volume | 57 |
| creator | CREW, J. P O'BRIEN, T BRADBURN, M FUGGLE, S BICKNELL, R CRANSTON, D HARRIS, A. L |
| description | Tumor development is angiogenesis dependent, and vascular endothelial growth factor (VEGF) is a key growth factor in this process. We demonstrate that high expression of VEGF mRNA in 55 superficial bladder cancers was associated with earlier recurrence (P = 0.001; hazard ratio, 3.09) and progression to a more invasive phenotype (P = 0.02; hazard ratio, 5.33). VEGF mRNA expression correlated with protein levels in superficial tumors (r = 0.59, P = 0.003) and normal bladder (r = 0.65, P < 0.05), although the ratio of VEGF protein to mRNA was elevated in tumors compared to normal bladder (P = 0.004), suggesting posttranscriptional regulation. In this study, VEGF is implicated as a major downstream mediator of the effects of the p53 tumor suppressor gene by the association between high p53 protein (determined immunochemically) and high VEGF protein and mRNA expression (P < 0.02), although in cases without high p53 protein expression, high VEGF mRNA also predicts a poor prognosis. The relationship between VEGF and early tumor recurrence suggests that seeding via angiogenesis may be a major mechanism in the pathogenesis of recurrence. These studies indicate that VEGF can predict the behavior of superficial bladder tumors and is a therapeutic target for intravesical therapy. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79449556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16329462</sourcerecordid><originalsourceid>FETCH-LOGICAL-h300t-9d3775c74b495a190c4300f644908ba28e99cc1e6b6f6c11700ada63846c530d3</originalsourceid><addsrcrecordid>eNqFkM1LxDAQxYMo67r6Jwg5iLdC2nw1R1n8ggUv6rVMk-luJNvWpEX87426ePU0vHk_HjPviCxLyetCCyGPyZIxVhdS6OqUnKX0lqUsmVyQheGGa8mWZHyFZOcAkWLvhmmHwUOg2zh8TDvagZ2GSH2iQMeIzv_IoaMRA4wJKfSOpgm2mO1hGzElP_TU9zTNI8bO2--wNoBzGKmF3mI8JycdhIQXh7kiL3e3z-uHYvN0_7i-2RQ7zthUGMe1llaLVhgJpWFW5H2nhDCsbqGq0RhrS1St6pQtS80YOFC8FspKzhxfkevf3HzZ-4xpavY-WQwBehzm1GiTo6RU_4Kl4pURqsrg5QGc2z26Zox-D_GzOXSZ_auDnyuF0MX8r09_WMVqXnHJvwDwyn5h</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16329462</pqid></control><display><type>article</type><title>Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>CREW, J. P ; O'BRIEN, T ; BRADBURN, M ; FUGGLE, S ; BICKNELL, R ; CRANSTON, D ; HARRIS, A. L</creator><creatorcontrib>CREW, J. P ; O'BRIEN, T ; BRADBURN, M ; FUGGLE, S ; BICKNELL, R ; CRANSTON, D ; HARRIS, A. L</creatorcontrib><description>Tumor development is angiogenesis dependent, and vascular endothelial growth factor (VEGF) is a key growth factor in this process. We demonstrate that high expression of VEGF mRNA in 55 superficial bladder cancers was associated with earlier recurrence (P = 0.001; hazard ratio, 3.09) and progression to a more invasive phenotype (P = 0.02; hazard ratio, 5.33). VEGF mRNA expression correlated with protein levels in superficial tumors (r = 0.59, P = 0.003) and normal bladder (r = 0.65, P < 0.05), although the ratio of VEGF protein to mRNA was elevated in tumors compared to normal bladder (P = 0.004), suggesting posttranscriptional regulation. In this study, VEGF is implicated as a major downstream mediator of the effects of the p53 tumor suppressor gene by the association between high p53 protein (determined immunochemically) and high VEGF protein and mRNA expression (P < 0.02), although in cases without high p53 protein expression, high VEGF mRNA also predicts a poor prognosis. The relationship between VEGF and early tumor recurrence suggests that seeding via angiogenesis may be a major mechanism in the pathogenesis of recurrence. These studies indicate that VEGF can predict the behavior of superficial bladder tumors and is a therapeutic target for intravesical therapy.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 9393750</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Biological and medical sciences ; Carcinoma, Transitional Cell - blood supply ; Carcinoma, Transitional Cell - mortality ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - surgery ; Disease Progression ; Disease-Free Survival ; Endothelial Growth Factors - analysis ; Endothelial Growth Factors - biosynthesis ; Humans ; Lymphokines - analysis ; Lymphokines - biosynthesis ; Medical sciences ; Neoplasm Staging ; Neovascularization, Pathologic ; Nephrology. Urinary tract diseases ; Predictive Value of Tests ; Prognosis ; Recurrence ; Reference Values ; RNA, Messenger - biosynthesis ; Survival Rate ; Time Factors ; Transcription, Genetic ; Tumor Suppressor Protein p53 - analysis ; Tumor Suppressor Protein p53 - biosynthesis ; Tumors of the urinary system ; Urinary Bladder - cytology ; Urinary Bladder - pathology ; Urinary Bladder Neoplasms - blood supply ; Urinary Bladder Neoplasms - mortality ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - surgery ; Urinary tract. Prostate gland ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors</subject><ispartof>Cancer research (Chicago, Ill.), 1997-12, Vol.57 (23), p.5281-5285</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2083235$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9393750$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CREW, J. P</creatorcontrib><creatorcontrib>O'BRIEN, T</creatorcontrib><creatorcontrib>BRADBURN, M</creatorcontrib><creatorcontrib>FUGGLE, S</creatorcontrib><creatorcontrib>BICKNELL, R</creatorcontrib><creatorcontrib>CRANSTON, D</creatorcontrib><creatorcontrib>HARRIS, A. L</creatorcontrib><title>Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Tumor development is angiogenesis dependent, and vascular endothelial growth factor (VEGF) is a key growth factor in this process. We demonstrate that high expression of VEGF mRNA in 55 superficial bladder cancers was associated with earlier recurrence (P = 0.001; hazard ratio, 3.09) and progression to a more invasive phenotype (P = 0.02; hazard ratio, 5.33). VEGF mRNA expression correlated with protein levels in superficial tumors (r = 0.59, P = 0.003) and normal bladder (r = 0.65, P < 0.05), although the ratio of VEGF protein to mRNA was elevated in tumors compared to normal bladder (P = 0.004), suggesting posttranscriptional regulation. In this study, VEGF is implicated as a major downstream mediator of the effects of the p53 tumor suppressor gene by the association between high p53 protein (determined immunochemically) and high VEGF protein and mRNA expression (P < 0.02), although in cases without high p53 protein expression, high VEGF mRNA also predicts a poor prognosis. The relationship between VEGF and early tumor recurrence suggests that seeding via angiogenesis may be a major mechanism in the pathogenesis of recurrence. These studies indicate that VEGF can predict the behavior of superficial bladder tumors and is a therapeutic target for intravesical therapy.</description><subject>Biological and medical sciences</subject><subject>Carcinoma, Transitional Cell - blood supply</subject><subject>Carcinoma, Transitional Cell - mortality</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - surgery</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Endothelial Growth Factors - analysis</subject><subject>Endothelial Growth Factors - biosynthesis</subject><subject>Humans</subject><subject>Lymphokines - analysis</subject><subject>Lymphokines - biosynthesis</subject><subject>Medical sciences</subject><subject>Neoplasm Staging</subject><subject>Neovascularization, Pathologic</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Reference Values</subject><subject>RNA, Messenger - biosynthesis</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Transcription, Genetic</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><subject>Tumor Suppressor Protein p53 - biosynthesis</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder - cytology</subject><subject>Urinary Bladder - pathology</subject><subject>Urinary Bladder Neoplasms - blood supply</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - surgery</subject><subject>Urinary tract. Prostate gland</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Vascular Endothelial Growth Factors</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1LxDAQxYMo67r6Jwg5iLdC2nw1R1n8ggUv6rVMk-luJNvWpEX87426ePU0vHk_HjPviCxLyetCCyGPyZIxVhdS6OqUnKX0lqUsmVyQheGGa8mWZHyFZOcAkWLvhmmHwUOg2zh8TDvagZ2GSH2iQMeIzv_IoaMRA4wJKfSOpgm2mO1hGzElP_TU9zTNI8bO2--wNoBzGKmF3mI8JycdhIQXh7kiL3e3z-uHYvN0_7i-2RQ7zthUGMe1llaLVhgJpWFW5H2nhDCsbqGq0RhrS1St6pQtS80YOFC8FspKzhxfkevf3HzZ-4xpavY-WQwBehzm1GiTo6RU_4Kl4pURqsrg5QGc2z26Zox-D_GzOXSZ_auDnyuF0MX8r09_WMVqXnHJvwDwyn5h</recordid><startdate>19971201</startdate><enddate>19971201</enddate><creator>CREW, J. P</creator><creator>O'BRIEN, T</creator><creator>BRADBURN, M</creator><creator>FUGGLE, S</creator><creator>BICKNELL, R</creator><creator>CRANSTON, D</creator><creator>HARRIS, A. L</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19971201</creationdate><title>Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer</title><author>CREW, J. P ; O'BRIEN, T ; BRADBURN, M ; FUGGLE, S ; BICKNELL, R ; CRANSTON, D ; HARRIS, A. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h300t-9d3775c74b495a190c4300f644908ba28e99cc1e6b6f6c11700ada63846c530d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biological and medical sciences</topic><topic>Carcinoma, Transitional Cell - blood supply</topic><topic>Carcinoma, Transitional Cell - mortality</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - surgery</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Endothelial Growth Factors - analysis</topic><topic>Endothelial Growth Factors - biosynthesis</topic><topic>Humans</topic><topic>Lymphokines - analysis</topic><topic>Lymphokines - biosynthesis</topic><topic>Medical sciences</topic><topic>Neoplasm Staging</topic><topic>Neovascularization, Pathologic</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Reference Values</topic><topic>RNA, Messenger - biosynthesis</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Transcription, Genetic</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><topic>Tumor Suppressor Protein p53 - biosynthesis</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder - cytology</topic><topic>Urinary Bladder - pathology</topic><topic>Urinary Bladder Neoplasms - blood supply</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - surgery</topic><topic>Urinary tract. Prostate gland</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Vascular Endothelial Growth Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CREW, J. P</creatorcontrib><creatorcontrib>O'BRIEN, T</creatorcontrib><creatorcontrib>BRADBURN, M</creatorcontrib><creatorcontrib>FUGGLE, S</creatorcontrib><creatorcontrib>BICKNELL, R</creatorcontrib><creatorcontrib>CRANSTON, D</creatorcontrib><creatorcontrib>HARRIS, A. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CREW, J. P</au><au>O'BRIEN, T</au><au>BRADBURN, M</au><au>FUGGLE, S</au><au>BICKNELL, R</au><au>CRANSTON, D</au><au>HARRIS, A. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1997-12-01</date><risdate>1997</risdate><volume>57</volume><issue>23</issue><spage>5281</spage><epage>5285</epage><pages>5281-5285</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Tumor development is angiogenesis dependent, and vascular endothelial growth factor (VEGF) is a key growth factor in this process. We demonstrate that high expression of VEGF mRNA in 55 superficial bladder cancers was associated with earlier recurrence (P = 0.001; hazard ratio, 3.09) and progression to a more invasive phenotype (P = 0.02; hazard ratio, 5.33). VEGF mRNA expression correlated with protein levels in superficial tumors (r = 0.59, P = 0.003) and normal bladder (r = 0.65, P < 0.05), although the ratio of VEGF protein to mRNA was elevated in tumors compared to normal bladder (P = 0.004), suggesting posttranscriptional regulation. In this study, VEGF is implicated as a major downstream mediator of the effects of the p53 tumor suppressor gene by the association between high p53 protein (determined immunochemically) and high VEGF protein and mRNA expression (P < 0.02), although in cases without high p53 protein expression, high VEGF mRNA also predicts a poor prognosis. The relationship between VEGF and early tumor recurrence suggests that seeding via angiogenesis may be a major mechanism in the pathogenesis of recurrence. These studies indicate that VEGF can predict the behavior of superficial bladder tumors and is a therapeutic target for intravesical therapy.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>9393750</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-5472 |
| ispartof | Cancer research (Chicago, Ill.), 1997-12, Vol.57 (23), p.5281-5285 |
| issn | 0008-5472 1538-7445 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79449556 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
| subjects | Biological and medical sciences Carcinoma, Transitional Cell - blood supply Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - surgery Disease Progression Disease-Free Survival Endothelial Growth Factors - analysis Endothelial Growth Factors - biosynthesis Humans Lymphokines - analysis Lymphokines - biosynthesis Medical sciences Neoplasm Staging Neovascularization, Pathologic Nephrology. Urinary tract diseases Predictive Value of Tests Prognosis Recurrence Reference Values RNA, Messenger - biosynthesis Survival Rate Time Factors Transcription, Genetic Tumor Suppressor Protein p53 - analysis Tumor Suppressor Protein p53 - biosynthesis Tumors of the urinary system Urinary Bladder - cytology Urinary Bladder - pathology Urinary Bladder Neoplasms - blood supply Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery Urinary tract. Prostate gland Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors |
| title | Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T08%3A07%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vascular%20endothelial%20growth%20factor%20is%20a%20predictor%20of%20relapse%20and%20stage%20progression%20in%20superficial%20bladder%20cancer&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=CREW,%20J.%20P&rft.date=1997-12-01&rft.volume=57&rft.issue=23&rft.spage=5281&rft.epage=5285&rft.pages=5281-5285&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E16329462%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16329462&rft_id=info:pmid/9393750&rfr_iscdi=true |